News

Article

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-04-01-2015
Volume11
Issue 4

Xcelience Receives DEA Approval for Schedule I Drug Products

Xcellience receives approval to handle both analytical and manufacturing of DEA Scheduled products.

 

Xcelience, a contract drug manufacturer, announced that the company has received approval from the US Drug Enforcement Agency (DEA) to develop and manufacture Schedule I controlled substances.  he license extension completes company’s approval to handle both analytical and manufacturing of DEA Scheduled products, according to a company statement. 

"Regulatory capability is a critical attribute for CDMOs," says Alex McClung, vice-president, quality at Xcelience. "This Schedule I-V license underscores our capability and extends our Suite of Services to a whole new class of therapeutic compounds."

In addition, Xcelience announced that the company is expanding its pharmaceutical development services and manufacturing capacity by adding a new facility in the Tampa area to include more pharmaceutical development labs, manufacturing, quality assurance and packaging services.  

Source: Xcellience

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content